Erbagci Zülal, Tuncel A Almila, Erbagci Ibrahim
Department of Dermatology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
J Drugs Dermatol. 2006 Jul-Aug;5(7):668-71.
Porokeratosis is a group of cutaneous disorders of keratinization characterized by a predisposition to malignant transformation. The condition, which may be associated with immune suppression, is usually resistant to therapy and has a high frequency of recurrence. Imiquimod, a potent topical immune response modifier with antiviral, antitumor, and immunoregulatory properties, is currently approved for the treatment of external anogenital warts and actinic keratosis. However, there have been also several reports demonstrating its efficacy in a variety of premalignant and malignant conditions. We report on 2 cases with immunosuppression-associated porokeratosis successfully treated with 5% topical imiquimod application.
汗孔角化症是一组角化性皮肤疾病，其特征是易于发生恶性转化。该病症可能与免疫抑制有关，通常对治疗有抗性且复发频率高。咪喹莫特是一种具有抗病毒、抗肿瘤和免疫调节特性的强效局部免疫反应调节剂，目前已被批准用于治疗外生殖器疣和光化性角化病。然而，也有几份报告证明其在多种癌前和恶性病症中有效。我们报告了2例免疫抑制相关汗孔角化症患者通过外用5%咪喹莫特成功治疗的病例。
